Oncobiologics, Inc. (NASDAQ:OTLK) Given Consensus Recommendation of “Hold” by Analysts

Oncobiologics, Inc. (NASDAQ:OTLK) has earned a consensus rating of “Hold” from the six analysts that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating on the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $4.50.

Several research firms have recently issued reports on OTLK. Weiss Ratings reissued a “sell (e+)” rating on shares of Oncobiologics in a research report on Friday, March 27th. Wall Street Zen lowered shares of Oncobiologics from a “hold” rating to a “sell” rating in a research report on Saturday, January 3rd. HC Wainwright reissued a “neutral” rating on shares of Oncobiologics in a research report on Wednesday, February 18th. Chardan Capital reissued a “neutral” rating on shares of Oncobiologics in a research report on Wednesday, February 18th. Finally, Ascendiant Capital Markets lowered their price target on shares of Oncobiologics from $10.00 to $6.00 and set a “buy” rating for the company in a report on Wednesday, March 11th.

Oncobiologics Stock Up 12.1%

Oncobiologics stock opened at $0.25 on Friday. Oncobiologics has a 52-week low of $0.16 and a 52-week high of $3.39. The firm has a fifty day moving average of $0.36 and a 200-day moving average of $0.99. The firm has a market capitalization of $21.07 million, a P/E ratio of -0.10 and a beta of 0.18.

Oncobiologics (NASDAQ:OTLK) last released its quarterly earnings data on Tuesday, February 17th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.05). The firm had revenue of ($1.21) million for the quarter, compared to the consensus estimate of $3.14 million. On average, research analysts expect that Oncobiologics will post -2.27 EPS for the current fiscal year.

Institutional Investors Weigh In On Oncobiologics

Large investors have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. grew its holdings in Oncobiologics by 865.2% during the 2nd quarter. Russell Investments Group Ltd. now owns 24,477 shares of the company’s stock valued at $39,000 after purchasing an additional 21,941 shares in the last quarter. AQR Capital Management LLC grew its holdings in Oncobiologics by 42.7% during the 1st quarter. AQR Capital Management LLC now owns 84,671 shares of the company’s stock valued at $103,000 after purchasing an additional 25,351 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its holdings in Oncobiologics by 74.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company’s stock valued at $126,000 after purchasing an additional 44,063 shares in the last quarter. 11.20% of the stock is owned by institutional investors and hedge funds.

Oncobiologics Company Profile

Oncobiologics, Inc is a clinical-stage biopharmaceutical company specializing in the development of biosimilar therapeutics for cancer and autoimmune diseases. Leveraging recombinant DNA technology and advanced formulation platforms, the company aims to create high-quality, cost-effective alternatives to originator biologic drugs. Oncobiologics’ research focus includes monoclonal antibodies and growth factors that support oncology treatment and immunomodulation.

Founded in 2005 and headquartered in Marlborough, Massachusetts, Oncobiologics maintains research facilities in the Greater Boston area and an integrated manufacturing site in Hyderabad, India, through its wholly owned subsidiary.